Journal: ESC Heart Failure

Article Title: Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction

doi: 10.1002/ehf2.13206

Figure Lengend Snippet: Characteristics of the overall population and of different subgroups

Article Snippet: We used commercially available ultrasound machines (Sonos 7500 and IE33, Philips Medical Systems, Andover, MA, USA; Vivid System 7, GE/Vingmed, Milwaukee, WI, USA).

Techniques:

Journal: ESC Heart Failure

Article Title: Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction

doi: 10.1002/ehf2.13206

Figure Lengend Snippet: Comparison between lung ultrasound B‐lines and chest X‐ray (CXR) signs of interstitial oedema

Article Snippet: We used commercially available ultrasound machines (Sonos 7500 and IE33, Philips Medical Systems, Andover, MA, USA; Vivid System 7, GE/Vingmed, Milwaukee, WI, USA).

Techniques: Comparison

Journal: ESC Heart Failure

Article Title: Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction

doi: 10.1002/ehf2.13206

Figure Lengend Snippet: Multivariable analysis of cardiopulmonary ultrasound parameters to predict the composite endpoint (cardiac mortality and rehospitalization for AHF) in the overall population, non‐AHF, HFrEF, and HFpEF

Article Snippet: We used commercially available ultrasound machines (Sonos 7500 and IE33, Philips Medical Systems, Andover, MA, USA; Vivid System 7, GE/Vingmed, Milwaukee, WI, USA).

Techniques:

Journal: ESC Heart Failure

Article Title: Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction

doi: 10.1002/ehf2.13206

Figure Lengend Snippet: Correlation between B‐lines and the ultrasound parameters that were found to be independent predictors of the composite endpoint

Article Snippet: We used commercially available ultrasound machines (Sonos 7500 and IE33, Philips Medical Systems, Andover, MA, USA; Vivid System 7, GE/Vingmed, Milwaukee, WI, USA).

Techniques:

Journal: Frontiers in Radiology

Article Title: Targeting the invisible: precision fiducial marker placement in poorly visible liver tumors prior to percutaneous ablation using real-time image fusion guidance

doi: 10.3389/fradi.2025.1659739

Figure Lengend Snippet: Cirrhotic patient with HCC scheduled for thermal ablation. A second small nodule was identified in the right liver during pre-procedural imaging. The objective was to localize this second nodule for percutaneous treatment during the same session. Lesion detection: (a) An 8 mm nodule is visualized on T2-weighted and T1 arterial-phase MRI, but not on T1 portal-phase imaging. (b) Fusion imaging was performed with T2 MRI. Due to anterior bowel interposition, an oblique intercostal approach was required. The nodule appeared as a slightly hypoechoic focus on ultrasound, although without certainty. Lesion localization: (c) The fiducial marker (white arrow) was placed under combined ultrasound and MR T2 fusion guidance. (d) Immediate post-procedural MRI confirmed the appropriate positioning of the marker in close contact with the nodule.

Article Snippet: Fusion was obtained using the software available on our ultrasound systems (Aplio 500, Toshiba Medical Systems Corp., Tokyo, Japan; EPIQ 7, Philips Healthcare, Andover, MA, USA).

Techniques: Imaging, Marker

Journal: Frontiers in Radiology

Article Title: Targeting the invisible: precision fiducial marker placement in poorly visible liver tumors prior to percutaneous ablation using real-time image fusion guidance

doi: 10.3389/fradi.2025.1659739

Figure Lengend Snippet: Hepatocellular carcinoma scheduled for thermal ablation. Lesion detection: (a) A 20 mm nodule is clearly seen on T1 MRI during both arterial and portal phases. (b) On CT, the lesion is detected at the arterial phase but not at the portal phase, highlighting potential difficulties for accurate targeting under CT guidance alone. Lesion localization: (c) Fusion imaging with T1 MRI arterial phase failed to directly visualize the nodule on ultrasound. However, adjacent vascular landmarks (hollow arrows) were concordant between MRI and ultrasound, allowing placement of the fiducial marker (white arrow) under ultrasound guidance by targeting the corresponding region. (d) Immediate post-procedural CT confirmed satisfactory marker positioning within the tumor volume.

Article Snippet: Fusion was obtained using the software available on our ultrasound systems (Aplio 500, Toshiba Medical Systems Corp., Tokyo, Japan; EPIQ 7, Philips Healthcare, Andover, MA, USA).

Techniques: Imaging, Marker

Journal: Frontiers in Radiology

Article Title: Targeting the invisible: precision fiducial marker placement in poorly visible liver tumors prior to percutaneous ablation using real-time image fusion guidance

doi: 10.3389/fradi.2025.1659739

Figure Lengend Snippet: Small recurrent hepatocellular carcinoma occurring 6 months after initial thermal ablation of a first lesion. Lesion detection: (a) A 10 mm nodule is identified adjacent to the ablation scar on T1 arterial-phase MRI, T2, and diffusion-weighted (b1000) imaging. It is not visible on portal-phase imaging. Lesion localization: (b) Fusion imaging with arterial-phase MRI did not allow confident visualization of the nodule. A fiducial marker was therefore placed under ultrasound guidance, posterior to the right hepatic vein (hollow arrow), in the region corresponding to the tumor on MRI. Due to poor echogenicity, the marker was not visualized on ultrasound after withdrawal of the applicator needle. (c) Immediate post-procedural CT showed the marker (white arrow) positioned approximately 4 cm anterior to the tumor. Despite this suboptimal placement, ablation could be performed under CT guidance by targeting posterior to the marker. (d) One-month follow-up MRI demonstrated an ablation zone encompassing the tumor, which was no longer visible.

Article Snippet: Fusion was obtained using the software available on our ultrasound systems (Aplio 500, Toshiba Medical Systems Corp., Tokyo, Japan; EPIQ 7, Philips Healthcare, Andover, MA, USA).

Techniques: Diffusion-based Assay, Imaging, Marker

Journal: Clinical Cardiology

Article Title: Diagnostic Accuracy and Cost‐Effectiveness of a Pocket‐Sized Transthoracic Echocardiographic Imaging Device

doi: 10.1002/clc.22171

Figure Lengend Snippet: Clinical Characteristics and Results of Standard Transthoracic Echocardiography Findings in Each Group

Article Snippet: Commercially available echocardiographic systems were used for sTTE examination, including iE‐33 (Philips Medical Systems, Andover, MA), Vivid7 and Vivid E9 (GE Medical Systems), Artida and Xario (Toshiba Medical Systems, Tokyo, Japan), and Sequoia 512 (Siemens Medical Solutions, Mountainview, CA).

Techniques: